FDA’s Parting Blow: A Legacy of Controversy Under Makary

The departure of Dr. Marty Makary as FDA commissioner marks a significant development in an agency already grappling with internal dysfunction and leadership turmoil. President Donald Trump has praised Makary as a “wonderful man,” but the reality is that his tenure was marked by controversy, including high-profile rejections of rare disease treatments and criticism from drugmakers, physicians, and patient groups.

Makary’s tenure was also characterized by a lack of transparency in regulatory decisions. The FDA’s initial refusal to review Moderna’s flu shot raised eyebrows within the biotech industry. Although the agency later reversed course on the vaccine, this incident highlights the complexities of relationships between regulators and industry stakeholders.

One contentious issue during Makary’s tenure was his handling of abortion-related policies. The FDA’s review of the abortion pill mifepristone was slow-walked by Makary, sparking criticism from organizations like Susan B. Anthony Pro-Life America, which had called for Makary’s ouster.

The pharmaceutical industry is cautious about a shakeup at the FDA, given its significant investments in regulatory processes and policy initiatives. As the agency reauthorizes the Prescription Drug User Act Fee, companies are likely wary of potential changes in leadership.

The Fallout Within

Staff morale at the FDA has plummeted following layoffs and departures of career agency scientists. Longtime cancer regulator Dr. Richard Pazdur cited Makary’s leadership as his reason for leaving. Remaining staff members have expressed growing distrust of leadership.

The appointment of Vinay Prasad, a vocal critic of the FDA within industry circles, as a key agency official overseeing vaccines and biotech treatments has further polarized the agency. Prasad’s rejection of a Huntington’s disease gene therapy from uniQure, which claimed the FDA was requiring fake brain surgery to evaluate treatment efficacy, sparked controversy.

A Legacy of Controversy

Makary’s tenure was marked by criticism from various stakeholders, including biotech companies and patient groups. The agency’s high-profile rejections of rare disease treatments have raised concerns about regulatory processes.

The FDA’s rejection of Replimune’s drug candidate for melanoma a second time has sparked debate over trial design and evidence requirements. Makary’s defense of the agency’s decisions, stating that three independent teams had arrived at the same conclusion around the treatment and no “corrupt sweetheart deals” were made, failed to quell concerns.

The Road Ahead

As Trump looks to install a new commissioner, securing support from Sen. Bill Cassidy will be crucial. However, Trump’s efforts may be complicated by his backing of a candidate trying to unseat Cassidy in Louisiana.

The FDA’s next commissioner will inherit the agency’s legacy under Makary, including the abortion pill review and the fallout within the agency. As the agency navigates its complex relationships with stakeholders, transparency and accountability must be prioritized.

In the end, the departure of Dr. Marty Makary serves as a reminder of the challenges facing the FDA: internal dysfunction, leadership turmoil, and the need for effective regulatory processes. The agency’s next steps will determine whether it can move forward effectively.